Celltrion said on the 2nd that it will showcase its autoimmune disease treatments at the 2025 United European Gastroenterology Week (UEGW), Europe's largest gastroenterology conference, to be held in Berlin, Germany, from the 4th to the 7th (local time).
The flagship product is Remsima SC (REMSIMA®; U.S. brand name Zymfentra). Remsima is a biosimilar of Johnson & Johnson (J&J)'s autoimmune disease treatment Remicade (infliximab), which Celltrion developed from the existing intravenous (IV) formulation into a subcutaneous (SC) formulation to improve patient convenience. Prescriptions are currently expanding rapidly, mainly in Europe and the United States.
At this conference, Celltrion will set up a standalone booth in the main exhibition hall and conduct expert sessions and academic and marketing activities for local medical professionals. The session will discuss prescription data for Remsima IV and SC formulations, comparisons of formulations in maintenance treatment for inflammatory bowel disease, and effective strategies for switching formulations.
In particular, post-hoc analysis results from a global phase 3 clinical trial of Remsima SC in patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD) will be presented. In a two-year study, the company compared patients who experienced loss of response (LoR)—in which efficacy declined or no longer worked during treatment—with those whose efficacy was maintained through the end. As a result, a clear difference emerged between the two groups from the start of treatment, confirming the potential to predict future loss of efficacy from the early stage of therapy.
Celltrion will also introduce Yuflyma (adalimumab), which has been rapidly expanding its market share in Europe recently. According to market research firm IQVIA, Yuflyma's European market share in the first quarter of this year was 24%, up 3 percentage points from the previous quarter, leaving just a 1 percentage point gap with the top product.
A Celltrion official said, "As we have consistently highlighted the excellence of Remsima SC at global conferences, we expect a positive response at this UEGW as well," adding, "We will do our best to enhance the competitiveness of our autoimmune disease treatment portfolio to drive prescription growth and expand market share."